GB1054698A - - Google Patents
Info
- Publication number
- GB1054698A GB1054698A GB1054698DA GB1054698A GB 1054698 A GB1054698 A GB 1054698A GB 1054698D A GB1054698D A GB 1054698DA GB 1054698 A GB1054698 A GB 1054698A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- acid
- ascorbic acid
- salt
- cackets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 2
- 235000010323 ascorbic acid Nutrition 0.000 abstract 2
- 239000011668 ascorbic acid Substances 0.000 abstract 2
- 229960005070 ascorbic acid Drugs 0.000 abstract 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004260 Potassium ascorbate Substances 0.000 abstract 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 abstract 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 229960002104 cyanocobalamin Drugs 0.000 abstract 1
- 235000000639 cyanocobalamin Nutrition 0.000 abstract 1
- 239000011666 cyanocobalamin Substances 0.000 abstract 1
- 229960002061 ergocalciferol Drugs 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 235000019152 folic acid Nutrition 0.000 abstract 1
- 239000011724 folic acid Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000007937 lozenge Substances 0.000 abstract 1
- 159000000003 magnesium salts Chemical class 0.000 abstract 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 abstract 1
- 229960001252 methamphetamine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229940055726 pantothenic acid Drugs 0.000 abstract 1
- 235000019161 pantothenic acid Nutrition 0.000 abstract 1
- 239000011713 pantothenic acid Substances 0.000 abstract 1
- 235000010603 pastilles Nutrition 0.000 abstract 1
- 235000019275 potassium ascorbate Nutrition 0.000 abstract 1
- 229940017794 potassium ascorbate Drugs 0.000 abstract 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 abstract 1
- 235000008160 pyridoxine Nutrition 0.000 abstract 1
- 239000011677 pyridoxine Substances 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 235000019192 riboflavin Nutrition 0.000 abstract 1
- 239000002151 riboflavin Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 235000019157 thiamine Nutrition 0.000 abstract 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- 239000011721 thiamine Substances 0.000 abstract 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 abstract 1
- 235000001892 vitamin D2 Nutrition 0.000 abstract 1
- 239000011653 vitamin D2 Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1,054,698. Pharmaceutical composition containing salts of ascorbic acid. N. J. FLOWER. Nov. 29, 1965 [Dec. 4, 1964], No. 49330/64. Heading A5B. A pharmaceutical composition comprises as active ingredients potassium ascorbate, a magnesium salt of ascorbic acid, and optionally glucose or a salt of carnitine, thiamine, methylamphetamine, riboflavin, niacin, niacinamide, pyridoxine, pantothenic acid, biotin, folic acid, cyanocobalamin or calciferol. The compositions are administered orally in the form of tablets, capsules, sachets, cackets, pastilles, troches or lozenges.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4933064 | 1964-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1054698A true GB1054698A (en) |
Family
ID=10451983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1054698D Active GB1054698A (en) | 1964-12-04 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE673254A (en) |
| FR (1) | FR5013M (en) |
| GB (1) | GB1054698A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4414212A (en) * | 1981-12-10 | 1983-11-08 | Graham J. Naylor | Method of treatment of pre-menstrual syndrome |
| US4704352A (en) * | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
| WO1999053921A1 (en) * | 1998-04-17 | 1999-10-28 | Sigma-Tau Healthscience S.P.A. | Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| WO2015176848A1 (en) * | 2014-05-21 | 2015-11-26 | Bauer K H | Self-drying dosage form with controllable drying time and drying rate |
-
0
- GB GB1054698D patent/GB1054698A/en active Active
-
1965
- 1965-12-03 BE BE673254D patent/BE673254A/xx unknown
- 1965-12-03 FR FR40816A patent/FR5013M/fr not_active Expired
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4414212A (en) * | 1981-12-10 | 1983-11-08 | Graham J. Naylor | Method of treatment of pre-menstrual syndrome |
| US4704352A (en) * | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
| WO1999053921A1 (en) * | 1998-04-17 | 1999-10-28 | Sigma-Tau Healthscience S.P.A. | Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| AU750645B2 (en) * | 1998-04-17 | 2002-07-25 | Sigma-Tau Healthscience S.P.A. | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH |
| WO2015176848A1 (en) * | 2014-05-21 | 2015-11-26 | Bauer K H | Self-drying dosage form with controllable drying time and drying rate |
Also Published As
| Publication number | Publication date |
|---|---|
| FR5013M (en) | 1967-04-24 |
| BE673254A (en) | 1966-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL36079A0 (en) | 4-morpholino-thieno (3,2-d) pyrimidine derivatives,their production and pharmaceutical compositions containing them | |
| IL36018A0 (en) | New 1,4-dihydropyridine derivatives,their production and pharmaceutical compositions containing them | |
| GB1204580A (en) | Pharmaceutical dosage forms | |
| HU172709B (en) | Process for producing diphenyl-ether derivatives and herbicide compositions containing them as active agents | |
| IL35729A0 (en) | 2-(5-nitro-2-furyl)-thieno (3.2-d) pyrimidines,their preparation and pharmaceutical compositions containing them | |
| HU170778B (en) | Fungicide compositions, and process for producing l-propyl-imidazole derivatives and salts thereof as active agents | |
| IL35078A (en) | 2-aminoalkylamino-thieno (3,2-d) pyrimidines and their salts,their preparation and pharmaceutical compositions containing them | |
| GB975387A (en) | Multivitamin compositions | |
| GB1054698A (en) | ||
| IL47937A0 (en) | Pharmaceutical compositions containing 6,8-diethyl-5-hydroxy-4-oxo-4h-1-benzopyran-2-carboxylic acid or a salt thereof | |
| HU175933B (en) | Process for producing 4-hydroxy-3,5-dialkyl-phenyl-propionic acid derivatives and pharmaceutical compositions containing ttem as active agents | |
| GB1191246A (en) | Vitamin-containing Preparations | |
| IE37292L (en) | Mineral salt preparation | |
| GB1202148A (en) | Pharmaceutical compositions | |
| DK123141B (en) | Process for stabilizing a pharmaceutical composition suitable for oral administration, containing a basic dihydrodibenzazepine. | |
| NL142589B (en) | METHOD FOR PREPARING STABLE Aqueous SOLUTIONS OF A SALT OF A 21-PHOSPHATE OF A 21-HYDROXYSTEROID SUITABLE FOR PARENTERAL ADMINISTRATION BY PHARMACY. | |
| CA936533A (en) | 5-aryl-2,3-dihydro-2,2(or 3,3) dimethyl-5h-imidazo(2,1-a) isoindol-5-ols and 2(4,4(5,5) dimethyl-2-imidazolin-2-yl) bensophenone acid addition salts and processes for their preparation | |
| ES255922A1 (en) | New piperazine derivative | |
| GB1446584A (en) | Agent for deodorising and influencing perspiration | |
| GB1187946A (en) | Dimethylbiguanide Derivative | |
| IL34938A0 (en) | Pharmaceutical compositions containing a 2,4-thiazolidine-dione-2 thiosemicarbazone derivatives | |
| ES264510A1 (en) | Improvements in or relating to pharmaceutical iron preparations | |
| GB1263839A (en) | A novel aminoethanesulfonic acid | |
| GB1153324A (en) | Sustained Release Tablets | |
| FI51900C (en) | A process for the preparation of tablets in which the active substance dissolves slowly. |